Home

MICHAEL NARACHI

CIK 1380022 · CEO & President · last filed 2026-05-18

MICHAEL NARACHI is a CEO & President who has filed 46 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for RARE, was dated May 18, 2026. Across all open-market trades the lifetime net is −$2.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.03M

Companies

4

Total Filings

46

Lifetime Open-Market Net

-$2.71M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RARE Director 40,441 $25.49 $1.03M $0 13 2026-05-18
Orexigen Therapeutics, Inc. (OREX) Delisted CEO & President 8,356 — — -$3.24M 22 2017-10-17
Eiger BioPharmaceuticals, Inc. (CLDN) Delisted Director 4,167 — — $500.0K 2 2015-06-05
AMAG PHARMACEUTICALS, INC. (AMAG) Delisted Director 23,900 — — $27.1K 9 2013-05-24

Recent Filings

46 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-18 RARE Grant (A) +7,751 $0 EDGAR
2025-05-19 RARE Grant (A) +5,740 $0 EDGAR
2024-06-20 RARE Grant (A) +5,345 $0 EDGAR
2023-06-09 RARE Grant (A) +3,860 $0 EDGAR
2022-06-28 RARE Grant (A) +3,300 $0 EDGAR
2021-06-28 RARE Grant (A) +2,145 $0 EDGAR
2020-06-30 RARE Grant (A) +2,550 $0 EDGAR
2019-06-13 RARE Grant (A) +3,000 $0 EDGAR
2018-06-20 RARE Grant (A) +3,000 $0 EDGAR
2017-10-17 Orexigen Therapeutics, Inc. (OREX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 46
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.